Health Innovations and Corporate Moves: A Global Perspective

A summary of recent health news includes Eli Lilly's expansion in India, a pending FDA review of processed carbohydrates, Danaher's acquisition plans, and Edwards Lifesciences' antitrust investigation closure. Additionally, Dr. Reddy's plans a discounted obesity drug launch while Compass Pathways reports breakthrough depression treatment results.

In the fast-evolving world of health, major corporations are making significant strides. Eli Lilly, a leading drugmaker, is setting its sights on India as a global export hub. This move comes amid booming sales of its obesity drug Mounjaro, which has quickly become a top seller.

Meanwhile, the U.S. Food and Drug Administration is considering revoking the safety status of certain processed carbohydrates. This comes after a petition urging the removal of corn syrup and other sweeteners from the GRAS list. Health Secretary Robert F. Kennedy Jr. highlighted this potential shift in regulations.

In corporate news, Danaher is closing in on a $10 billion deal to acquire Masimo, while Edwards Lifesciences ends its anti-copycat policy following an EU investigation. Dr. Reddy's Laboratories aims to introduce a cost-effective generic obesity drug, and Compass Pathways reports positive results for their psilocybin-based depression therapy.

(With inputs from agencies.)